Pharmaceutical Technology

FEBRUARY 3, 2023

However, after almost seven years of staving off competitors through patents and litigation, Humira’s market-leading position in the US will be affected as Amgen’s adalimumab biosimilar, Amjevita, started to roll out on January 31, 2023. billion in 2022.

Marketing 52

Marketing Sales Patients Physicians 52

Pharmaceutical Technology

APRIL 4, 2023

While Scorpion will lead the development of STX-721, Pierre Fabre will handle STX-241. According to GlobalData’s Pharma Intelligence Centre, Tagrisso is forecasted to have global sales of $8.19 billion in 2029. Up to 12.5% of NSCLC patients with exon 19 and 21 mutations develop resistance mutations at C797S.

Food and Drug Administration 52

Food and Drug Administration Biopharma FDA Pharmaceutical 52

pharmaphorum

DECEMBER 20, 2022

Wedbush Securities recently forecast more than $1 billion in 2029 sales for ensifentrine in the US alone, assuming a launch in the first quarter of 2024, and said today the stock could easily reach $30. COPD is the third leading cause of death worldwide, with 3.23 and drive the company’s market cap to almost $1.5

Pharma 57

Pharma Sales Leads Marketing 57

PM360

APRIL 7, 2023

Pharma, formulary decision-makers, and contracting specialists must now track exact dates when drugs became available, then track the difference between average sales price (ASP) and Maximum Fair Price (MFP) to ensure provider reimbursement is correct.”

Marketing 52

Marketing Pharma Manufacturing Healthcare 52

European Pharmaceutical Review

JANUARY 18, 2024

In its report on the insomnia market published last month, GlobalData expected that sales for DORAs, which offer a new mechanism of action for the condition, will continue to grow at a CAGR of 8.6 GlobalData’s Analyst covering Neurology and Ophthalmology, Thomas Parker, MPharmacol, predicted that Belsomra would lead the market by 2023.

Marketing 88

Marketing Sales Pharmacology Pharma 88

Pharmaceutical Technology

JUNE 12, 2023

In 2022, the FDA awarded VX-548 breakthrough therapy and fast-track designations for post-operative pain, and the drug is forecast to reach sales of $416m by 2029. A promising example includes Vertex Pharmaceuticals’s VX-548, a sodium channel subunit blocker. Six cannabinoids have recently completed or are undergoing Phase II trials.

Medical 143

Medical Prescription Management Manufacturing 143

Spotio

MAY 7, 2024

There’s never been a better time to be in telecom sales. billion in the US alone by 2029. In other words, there’s plenty of opportunity—as long as you know how to generate telecom sales leads effectively, of course. Building ICPs for your sales team will keep your reps focused. The result?

Leads 52

Leads Sales Prospecting Distribution 52

Pharmaceutical Technology

MAY 17, 2023

This results in bile buildup in the liver and can lead to scarring. According to consensus forecasts from GlobalData’s Pharma Intelligence Centre, Ocaliva is forecasted to have global sales of $1.08 billion in 2029. The condition gradually worsens and can result in liver failure.

Food and Drug Administration 52

Food and Drug Administration FDA Pharmaceutical Prospecting 52